Does chemotherapy have a role as palliative therapy for unfit or elderly patients with non-small-cell lung cancer?

Abstract

Elderly patients and younger "unfit" patients with poor Eastern Cooperative Oncology Group (ECOG) performance status (PS) (> or = 2) suffering from advanced non-small-cell lung cancer (NSCLC) are two different populations--both of which require palliative treatments. Elderly patients frequently experience progressive decline of organ function and multiple comorbidities, which need to be considered when choosing therapy. ECOG 1594 showed that advanced NSCLC patients with an ECOG PS of 2 did not tolerate platinum-based chemotherapy (cisplatin/paclitaxel, carboplatin/paclitaxel, cisplatin/docetaxel, carboplatin/paclitaxel). These data confirm that treatments designed specifically for this patient subset are needed. Single-agent chemotherapy seems to be a reasonable approach, and non-platinum-based combination chemotherapy should also be investigated. The oncology community has become increasingly aware of the magnitude of the problem of cancer in the elderly. More than 30% of lung cancers arise in patients > or = 70 years old. Elderly patients tolerate chemotherapy poorly, according to the few published papers, and are not considered eligible for aggressive cisplatin-based chemotherapy in clinical practice. A phase III randomized trial (ELVIS [Elderly Lung Cancer Vinorelbine Italian Study]) demonstrated survival and quality-of-life benefits with single-agent vinorelbine versus best supportive care. Among the newer drugs, gemcitabine has demonstrated activity and low toxicity in phase II studies. With this background, we performed a randomized, multicenter phase III trial (MILES [Multicenter Italian Lung Cancer in the Elderly Study]) in 707 advanced NSCLC elderly patients. The MILES study compared single-agent chemotherapy with vinorelbine or gemcitabine versus polychemotherapy with gemcitabine plus vinorelbine. Results showed no benefit in response rate, time to progression, survival, and quality of life for the combination. Single-agent chemotherapy remains the standard treatment approach for elderly NSCLC patients with advanced disease.

• Authors: Cesare Gridelli
• Journal: Lung cancer (Amsterdam, Netherlands) (Lung Cancer) Vol. 38 Suppl 2 Pg. S45-50 (Nov 2002) ISSN: 0169-5002 [Print] Ireland
• PMID: 12431829 (Publication Type: Journal Article, Review)
• Copyright: Copyright 2002 Elsevier Science Ireland Ltd.

Chemical References

• Deoxycytidine
• Cisplatin
• Gemcitabine

Topics

• Aged
• Aging
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Carcinoma, Non-Small-Cell Lung (drug therapy, pathology)
• Cisplatin (administration & dosage)
• Clinical Trials as Topic
• Deoxycytidine (administration & dosage, analogs & derivatives)
• Drug Administration Schedule
• Humans
• Lung Neoplasms (drug therapy, pathology)
• Palliative Care
• Quality of Life
• Survival
• Gemcitabine